Evans R W, Manninen D L, Dong F B, Frist W H, Kirklin J K
Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905.
Ann Thorac Surg. 1993 Aug;56(2):343-5. doi: 10.1016/0003-4975(93)91173-k.
Substantial progress has been made in clinical heart-lung transplantation. Although outcomes vary across centers, 1-year patient survival is now 59%. This study was an attempt to assess consensus among transplant program directors regarding the major determinants of patient outcome. In the National Cooperative Transplantation Study we evaluated consensus through a survey of all heart-lung transplant programs active in 1988. Of the eligible programs, 23 (85%) returned completed surveys. Data on the medical and surgical determinants of outcome were analyzed. There was considerable consensus among program directors as to the importance of several factors. The three most critical predictors of favorable outcomes were periodic pulmonary function tests to detect rejection (85.7%), avoidance of use of prednisone during the first 14 days after transplantation (76.2%), and annual left and right heart catheterization with coronary arteriography (76.2%). Several approaches were considered undesirable or unnecessary. These included electrocardiogram as standard rejection monitoring technique (71.4%), cytoimmunological monitoring as standard rejection monitoring technique (66.7%), and routine steroid discontinuation after transplantation (66.7%). On various other treatment approaches there was little evidence of consensus. These included prophylaxis with acyclovir and severe bronchiolitis as a criterion for retransplantation. Although controversial, consensus conferences are one means by which to evaluate technological innovations. Based on their results, practice guidelines can be developed to better inform third-party payers on issues related to transplantation.
临床心肺移植已取得重大进展。尽管各中心的结果有所不同,但目前患者1年生存率为59%。本研究旨在评估移植项目主任对患者预后主要决定因素的共识。在国家合作移植研究中,我们通过对1988年所有活跃的心肺移植项目进行调查来评估共识。在符合条件的项目中,23个(85%)返回了完整的调查问卷。对结果的医学和手术决定因素数据进行了分析。项目主任们对几个因素的重要性达成了相当程度的共识。预后良好的三个最关键预测因素是定期进行肺功能测试以检测排斥反应(85.7%)、移植后前14天避免使用泼尼松(76.2%)以及每年进行左右心导管检查和冠状动脉造影(76.2%)。有几种方法被认为不理想或不必要。这些包括将心电图作为标准排斥监测技术(71.4%)、将细胞免疫监测作为标准排斥监测技术(66.7%)以及移植后常规停用类固醇(66.7%)。在各种其他治疗方法上,几乎没有达成共识的证据。这些包括用阿昔洛韦进行预防以及将严重细支气管炎作为再次移植的标准。尽管存在争议,但共识会议是评估技术创新的一种方式。根据会议结果,可以制定实践指南,以便更好地向第三方付款人通报与移植相关的问题。